BSF Enterprise PLC - Successful Cultivated Meat Test
Released
Released
Announcement PDF
RNS Number : 8976A
BSF Enterprise PLC
30 May 2023
30 May 2023
BSF Enterprise PLC
("BSF" or the "Company")
Successful Cultivated Meat Test
BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based
clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that it has successfully produced a
further two full-scale fillets of cultivated pork, as well as a cultivated pork strip, which were presented at a
technical event on Friday 25 May 2023.
The cultivated pork fillets each measured 5 cm in diameter, 3 cm in height, and circa 60 g in weight, making them
similar in size to traditional 2-ounce tenderloin steaks. This time, the Company had worked on increasing the
thickness of the fillet in comparison to the fillet produced in January this year. In addition, the Company produced
a cultivated pork strip, or 'noodle' measuring circa 30 cm in length and 1 cm in diameter. The development of the
pork strip demonstrates the effectiveness of the Company's intellectual property in being applied to produce
meat in the future as a consumer-ready, 'pre-sliced' form for cooking purposes.
The cultivated meat products were produced using 3DBT's patented, serum-free and animal-free cell booster CityMixTM , which eliminates the requirement of conventional plant-based scaffolds, blends or fillers, as have been
universally adopted by the industry to date to ensure structural integrity of cultivated meat products. 3DBT's
products are therefore 100% structured meat, produced without any animals suffering in its production.
The latest iteration of 100% meat products underwent testing, with data collected and study participants invited
to inspect the product in a raw and cooked state. Study participants were limited to those persons who had a direct
working relationship or involvement with the Company. The cultivated meat fillets were then pan-fried and presented
formally by a trained, independent chef, while the meat strip was first cut in two portions, and subsequently
poached or pan-fried, in order to test an array of cooking methods. The chef's involvement was key to
demonstrating that the cultivated meat could be handled and cooked in the same way as traditional meat, and
the results were very positive.
The Company is pleased to confirm that the 100% cultivated meat products were very similar in appearance to
conventional meat in their raw state, with fibres clearly visible. The results from cutting and cooking the fillets
were also consistent with the previous results in terms of overall appearance, aroma and searing/crisping. The
Study participants that tasted the cultivated meat provided very positive feedback in terms of its taste and
texture.
Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues, commented: "We have gained
a huge amount of valuable knowledge from testing our products with a trained chef and we were reassured to observe
that our cultivated meat is able to be handled and cooked in the same way as traditional meat products. Further, data
collected from the study participants indicated comparable meat qualities to traditional pork meat, which was very
pleasing and highly validating of our work. This gives us further confidence as we continue our conversations with potential
customers to licence out the technologies demonstrated as well as building on the agreements already secured."
Photographs of the cultivated meat products in raw and cooked states from the Test Event can be found below:
A person in a white coat and gloves preparing food Description automatically generated with low
confidence
The raw fillets and pork strip.
A picture containing food, dish, garnish, cuisine Description automatically generated
The cooked pork fillets.
A plate of food with a bowl of sauce Description automatically generated with low confidence
A portion of the cooked pork strip.
-Ends-
For further enquiries, please visit www.bsfenterprise.com or contact:
BSF Enterprise PLC
Che Connon - CEO & Executive Director
Geoff Baker - Executive Director
Shard Capital (Broker)
Damon Heath
0203 971 7000
0207 1869 927
Isabella Pierre
SEC
Newgate
Communications)
Bob Huxford
Elisabeth Cowell
George Esmond
Via SEC Newgate below
(Financial
020 3757 6882
BSF@secnewgate.co.uk
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions
- using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as
human corneas, collagen growth and skin substitutes, as part of a radical transformation to
deliver sustainable solutions across a variety of sectors.
It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is
already producing human corneas to help restore vision to millions of people. Building on this
success, it has produced the UK's first high quality lab-grown meat from its laboratory using its
technology.
BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's
IP, which has multiple applications, as well as acquiring complementary businesses. It aims to
acquire a suite of technologies that underpins the development of tissue templating for corneas,
meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help
manufacture the products at scale.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of
this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy
Policy.
END
MSCEANSNALXDEFA
Share your feedback
Discover